Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Articles published by Arcturus Therapeutics Holdings Inc.

< Previous 1 2 Next >
Arcturus Therapeutics to Present at Jefferies London Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
Japan’s Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics’ Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT ASX:CSL CSLLY OTC
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Positive Development for Cystic Fibrosis Program
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 8, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at the Barclays 26th Annual Global Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Receives Orphan Medicinal Product Designation from the European Commission (EC), for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on March 7, 2024
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics’ ARCT-154, the First Self-Amplifying mRNA Vaccine Approved for COVID in Adults
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT ASX:CSL CSLLY
Arcturus Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ARCT-032, for the Treatment of Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Announces Third Quarter 2023 Financial Update and Pipeline Progress
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 14, 2023
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Awarded Additional Financial Grants from Japanese Government
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA (mRNA) Therapeutic to Treat Cystic Fibrosis
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
Study Shows Novel sa-mRNA Vaccines Offer Robust, Broad, Enduring Protection Against COVID-19 Variants
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Tickers ARCT
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.